Amarin (AMRN) Corporation announced that Italy’s National Health Service approved VAZKEPA for national reimbursement to reduce cardiovascular risk in eligible high-risk patients, as published in the Official Journal of the Italian Republic.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRN: